FMP
Royalty Pharma plc
RPRX
NASDAQ
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
32.45 USD
0.16 (0.493%)
RPRX Financial Statements
Year
2024
2023
2022
2021
CF from Operating Activities
2.77B
2.99B
2.14B
2.02B
Net Income
1.33B
1.7B
230.06M
1.24B
Depreciation & Amortization
0
0
5.67M
23M
Deferred Income Taxes
0
0
0
0
Stock Based Compensation
2.34M
2.36M
2.17M
2.44M
Change in Working Capital
53.38M
5.38M
32.66M
-16.32M
Accounts Receivable
-4.55M
-1.52M
-4.74M
-29.14M
Inventory
0
0
0
0
Accounts Payable
-2.29M
6.24M
2.29M
-4.59M
Other Working Capital
60.22M
667k
35.12M
17.41M
Other Non-Cash Items
1.38B
1.28B
1.87B
767.22M
CF from Investing Activities
-2.68B
-2.07B
-1.03B
-1.87B
Investments in Property, Plant & Equipment
0
0
0
0
Net Acquisitions
-10.96M
-12.54M
-9.9M
-34.85M
Investment Purchases
-2.74B
-2.12B
-2.57B
-3.59B
Sales/Maturities of Investments
118.36M
25.83M
1.55B
1.78B
Other Investing Activites
-49.32M
29.44M
0
-18.08M
CF from Financing Activities
361.14M
-2.15B
-944.86M
385.11M
Debt Repayment
1.47B
-1B
0
1.27B
Common Stock Issued
0
0
0
0
Common Stock Repurchased
-229.65M
-304.76M
0
0
Dividends Paid
-376.46M
-358.33M
-333.32M
-285.18M
Other Financing Activites
-503.97M
-485.67M
-611.53M
-602.24M
Free Cash Flow
2.77B
2.99B
2.14B
2.02B
Operating Cash Flow
2.77B
2.99B
2.14B
2.02B
Capital Expenditures
0
0
0
0
Cash at Beginning of Period
477.01M
1.71B
1.54B
1.01B
Cash at End of Period
929.03M
477.01M
1.71B
1.54B
Net Change In Cash
452.02M
-1.23B
169.7M
532.37M
Retained Earning Schedule
Year
2024
2023
2022
2021
Retained Earnings (Previous Year)
2.52B
1.96B
2.26B
1.92B
Net Income
859M
1.13B
42.83M
478.75M
Stock Repurchases
-229.65M
-304.76M
0
0
Dividend Paid
-376.46M
-358.33M
-333.32M
-285.18M
Retained Earnings
2.85B
2.52B
1.96B
2.26B
Other Distributions
-278.05M
-110.19M
-623.81M
49.36M
PPE Schedule
Year
2024
2023
2022
2021
Gross PPE
0
0
0
0
Annual Depreciation
0
395.13M
5.67M
23M
Capital Expenditure
0
0
0
0
Net PPE
0
-395.13M
-5.67M
-23M
Intangible and Goodwill Schedule
Year
2024
2023
2022
2021
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
